Skip to main content

Advertisement

SpringerLink
Log in

Limitations of “Classic” Risk Factors to Predict Neoadjuvant Chemotherapy Response for Operable Breast Cancer

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Shien T, Akashi-Tanaka S, Miyakawa K et al (2008) Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg 33:44–51

    Article  Google Scholar 

  2. Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33

    Article  PubMed  Google Scholar 

  3. Ziogas D, Baltogiannis G, Fatouros M et al (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715

    Article  PubMed  Google Scholar 

  4. Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197

    Article  PubMed  CAS  Google Scholar 

  5. Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and interactions with the environment may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9:1–6

    Article  PubMed  CAS  Google Scholar 

  6. Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141

    Article  PubMed  Google Scholar 

  7. Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8:587–597

    Article  PubMed  Google Scholar 

  8. Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8:29–39

    Article  PubMed  CAS  Google Scholar 

  9. Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358:1636

    Article  PubMed  CAS  Google Scholar 

  10. Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol [Epub ahead of print Feb 2, 2009]. doi:10.1200/JCO.2008.20.2812

  11. Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Unit, 1st Department of Propaedeutic Surgery, University of Athens, 114, Vas. Sofias Ave, Athens, 116 27, Greece

    Georgios C. Zografos & Dimosthenis Ziogas

Authors
  1. Georgios C. Zografos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimosthenis Ziogas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios C. Zografos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zografos, G.C., Ziogas, D. Limitations of “Classic” Risk Factors to Predict Neoadjuvant Chemotherapy Response for Operable Breast Cancer. World J Surg 33, 1545–1546 (2009). https://doi.org/10.1007/s00268-009-9933-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-009-9933-5

Keywords

Search

Navigation